Coinfection

Treatment of Hepatitis C in HIV Patients is Cost-Effective

Published in Hepatitis Weekly, November 20th, 2000

Treatment of hepatitis C virus (HCV) infection in patients co-infected with HIV is cost-effective, researchers in the United States assert.

"The majority of persons infected with HIV from intravenous drug use are co-infected with HCV and are at higher risk of progression to advanced liver disease and hepatocellular carcinoma than their HIV negative counterparts," stated F.C. Baldamus and colleagues from Harvard School of Medicine, Massachusetts. "Combination therapy with interferon-alpha2b and ribavirin is expensive, but has been shown to be cost-effective in HIV negative persons. Our objective was to assess the cost-effectiveness of combination therapy for HCV in HIV...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2000-11-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry